FRANK E. MOTT to Middle Aged
This is a "connection" page, showing publications FRANK E. MOTT has written about Middle Aged.
Connection Strength
0.119
-
Advance Care Planning and End-of-Life Issues in Head and Neck Cancer. J Palliat Care. 2019 Jan; 34(1):18-20.
Score: 0.025
-
Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy. Oral Oncol. 2018 06; 81:75-80.
Score: 0.024
-
Brain metastases in N2-positive non-small-cell lung cancer: implications for prophylactic cranial irradiation. Clin Lung Cancer. 2008 Jul; 9(4):227-9.
Score: 0.012
-
Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer. Clin Lung Cancer. 2003 Nov; 5(3):174-6.
Score: 0.009
-
Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709.
Score: 0.008
-
Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2021 07 01; 147(7):615-623.
Score: 0.008
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.008
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
Score: 0.007
-
Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncol. 2021 02; 113:105125.
Score: 0.007
-
Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1029-1035.
Score: 0.006
-
Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy. Clin Lung Cancer. 2018 07; 19(4):e517-e528.
Score: 0.006